Topper James N
SEC-identified person · CIK 1341382 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Phathom Pharmaceuticals, Inc. PHAT | Director | filed 2019–2026 |
| MBX Biosciences, Inc. MBX | Officer | filed 2024–2025 |
| Hillevax, Inc. HLVX | Officer | filed 2022–2025 |
| Newamsterdam Pharma Co N.V. NAMS | Director | filed 2023–2025 |
| Nivalis Therapeutics, Inc. NVLS | Director | filed 2017–2024 |
| Arcutis Biotherapeutics, Inc. ARQT | Officer | filed 2020–2023 |
| Anaptysbio, INC ANAB | Director | filed 2017–2023 |
| Frazier Lifesciences Acquisition Corp FLAC | Director · Chief Executive Officer | filed 2020–2020 |
| Allena Pharmaceuticals, Inc. ALNA | Director | filed 2017–2020 |
| Tarsus Pharmaceuticals, Inc. TARS | Officer | filed 2020–2020 |
| Aptinyx Inc. APTX | Director | filed 2018–2020 |
| Passage BIO, Inc. PASG | Officer | filed 2020–2020 |
| Entasis Therapeutics Holdings Inc. [ETTX] | Director | filed 2018–2020 |
| Mirum Pharmaceuticals, Inc. MIRM | Officer | filed 2019–2019 |
| Sierra Oncology, Inc. SRRA | Director | filed 2015–2017 |
| Glaukos Corp GKOS | Officer | filed 2015–2015 |
| Collegium Pharmaceutical, INC COLL | Officer | filed 2015–2015 |
| Amicus Therapeutics, INC. [FOLD} | Director | filed 2007–2014 |
| Portola Pharmaceuticals INC PTLA | Director | filed 2013–2013 |
| LA Jolla Pharmaceutical CO LJPC.QB | Director | filed 2006–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.